Somapacitan-beco
Sogroya (generic: somapacitan-beco) is a prescription injection solution made by Novo Nordisk for subcutaneous use. It contains somapacitan at 3.3 mg/mL strength and was approved under BLA761156, with marketing starting in May 2023. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Sogroya (generic: somapacitan-beco) is a prescription injection solution made by Novo Nordisk for subcutaneous use. It contains somapacitan at 3.3 mg/mL strength and was approved under BLA761156, with marketing starting in May 2023. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Somapacitan-beco",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Somapacitan-beco — ANDA 761156 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156"
}
]
|
| identifier | ANDA761156 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"health-care",
"pharmaceuticals",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Somapacitan-beco |
